In this study, we analyzed the frequency of circulating Treg cells one week after anti-PD-1 immunotherapy and their correlation alone or together with other suppressive immune cells and clinical outcomes including progression-free survival (PFS) and overall survival (OS) in advanced NSCLC patients. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.